PMID: 11921434Mar 29, 2002Paper

Differentiating members of the thiazolidinedione class: a focus on efficacy

Diabetes/metabolism Research and Reviews
Barry J Goldstein

Abstract

The thiazolidinediones (TZDs) or 'glitazones' are a new class of drug used for the treatment of type 2 diabetes. Although their precise mechanism of action is not known, TZDs target insulin resistance directly and thus tackle an underlying cause of the disease. Two TZDs are indicated for use in type 2 diabetes in the USA, pioglitazone and rosiglitazone. A third, troglitazone, has been associated with significant hepatotoxicity and has been withdrawn from use. In clinical trials, all three TZDs effectively lower blood glucose levels as monotherapy and in combination therapy with sulfonylureas, metformin and insulin. To date, head-to-head comparative studies with these agents have not been performed. It is difficult, therefore, to make direct comparisons of their efficacy since other variables, including baseline glucose levels and study design, can have a significant impact on treatment outcome. Despite this and in light of unique safety issues characterized with certain TZDs, it is useful to look closely at the efficacy data for these agents. It is not sufficient to assume that 'all glitazones are the same' because the studies have not yet been done to support this statement. This article will review what is known about the rel...Continue Reading

References

Jun 1, 1997·Journal of Clinical Epidemiology·T van StaaJ Monette
Mar 27, 1998·The New England Journal of Medicine·S E InzucchiG I Shulman
Mar 28, 1998·The New England Journal of Medicine·P B Watkins, R W Whitcomb
Feb 26, 2000·Diabetic Medicine : a Journal of the British Diabetic Association·B H WolffenbuttelR N Patwardhan
Feb 7, 2001·JAMA : the Journal of the American Medical Association·V FonsecaA Salzman
Mar 7, 2001·The Journal of Clinical Endocrinology and Metabolism·H E LebovitzUNKNOWN Rosiglitazone Clinical Trials Study Group

❮ Previous
Next ❯

Citations

May 27, 2005·International Journal of Obesity : Journal of the International Association for the Study of Obesity·M C CarmonaL Pénicaud
Sep 20, 2006·International Journal of Clinical Practice·J Wilding
Oct 12, 2010·Pharmaceuticals·Johanna K Distefano, Richard M Watanabe
Apr 10, 2003·Mayo Clinic Proceedings·Farhad ZangenehAnanda Basu
Jan 18, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·C ShettyS Ramachandran
Dec 18, 2003·The American Journal of Medicine·Norman K Hollenberg
Nov 25, 2004·Metabolism: Clinical and Experimental·Nobuyoshi NorisadaKazuwa Nakao
Mar 1, 2004·Current Therapeutic Research, Clinical and Experimental·Deborah GriffisRob Thwaites
Jul 21, 2015·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Alyssa M KeilPeter J Harvison
Oct 27, 2005·Diabetes·Johanna K WolfordRichard M Watanabe
Apr 10, 2008·The Annals of Pharmacotherapy·Moustafa Hm El-NaggarBassil Habib
Dec 14, 2004·Southern Medical Journal·Lisa L Willett, Eric S Albright
Apr 15, 2008·Clinical Drug Investigation·Patrizio TattiDomenico Merante
Mar 12, 2004·Drugs & Aging·Rukmini RajagopalanFrederick T Murray
Oct 25, 2002·Diabetes/metabolism Research and Reviews
Aug 21, 2007·Diabetes·Maria Carmen CarmonaUNKNOWN Consortium of the French Ministry of Research and Technology
Oct 27, 2004·Diabetes Care·Anita SarkerSteven C Martin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.